Building AI Foundation Models for Molecular Design

Boltz co-founders Jeremy Wohlwend and Gabriele Corso discuss with A16Z's Jorge Conde and Zach Dorrick the launch of Boltz, a public benefit company creating AI infrastructure for molecular biology. The discussion centers on how AI is transforming the understanding, modeling, and engineering of biology, impacting drug discovery. The open-source models, including Boltz1, Boltz2, and BoltzGen, accelerate adoption across academia and industry by modeling protein interactions and predicting binding strength. BoltzLab, the company's platform, integrates protein and small molecule design agents into scientific workflows, and partnerships, such as the one with Pfizer, aim to refine models using proprietary data. The goal is to make frontier biomolecular AI accessible, enabling scientists to design human-ready molecules and accelerate drug discovery.